| Pros and Cons of Aggressive Blood Pressure Lowering in Patients with Type 2 Diabetes. | |
| | |
MedLine Citation:
|
PMID: 22239626 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
The goal of treating hypertension in patients with diabetes is reduction of macrovascular and microvascular complications. Most current guidelines recommend more aggressive treatment goals with blood pressure (BP) targets of <130/80mmHg. Retrospective data analyses suggest an association between a lower BP and slower declines in chronic kidney disease (CKD) as well as greater cardiovascular (CV) risk reduction in patients with Type 2 diabetes. Such recommendations, however, are not supported by appropriately powered prospective outcome trials. Indeed, several important questions regarding aggressive lowering of BP levels are still unanswered. Major limitations of most existing clinical trials of BP lowering in diabetes is the failure to either target or achieve mean systolic BP values below 130mmHg. Data from more recent randomized trials that evaluated different levels of BP do not support a BP below 130/80 mmHg as providing further CV risk reduction and compared to levels below 140/90 mmHg. One consistent benefit of a lower BP level, however, is on reduction of cerebrovascular events. There is reasonable evidence that a lower BP level does further slow progression of advanced proteinuric kidney disease such that a BP goal <130/80 mmHg is defensible. This review examines the data for and against aggressive BP lowering in patients with diabetes. |
| | |
Authors:
|
Rigas G Kalaitzidis; George L Bakris |
Related Documents
:
|
6387316 - Comparison of plasma insulin profiles after subcutaneous administration of insulin by j... 6989436 - Timing of pre-breakfast insulin injection and postprandial metabolic control in diabeti... 21738896 - The association of unintentional changes in weight, body composition, and homeostasis m... 19698066 - Comparison of usability and patient preference for insulin pen needles produced with di... 20521326 - Impact of serotonin receptor 2a gene haplotypes on c-peptide levels in clozapine- and o... 18643776 - Effects of plasma membrane ca(2+)-atpase overexpression upon d-glucose metabolism in in... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-1-13 |
Journal Detail:
|
Title: Current vascular pharmacology Volume: - ISSN: 1875-6212 ISO Abbreviation: - Publication Date: 2012 Jan |
Date Detail:
|
Created Date: 2012-1-13 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101157208 Medline TA: Curr Vasc Pharmacol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Hypertensive Diseases Unit, University of Chicago-Pritzker School of Medicine, 5841 S. Maryland Ave MC 1027, Chicago, IL 60637, USA. gbakris@gmail.com. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Pathogenesis and Treatment Options.
Next Document: Recent Developments on Coronary Microvasculopathy after Heart Transplantation: A New Target in the T...